Dr. Lal Pathlabs Maintains Superior Execution In Q3: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Dr. Lal Pathlabs Ltd.’s Q3 FY21 performance was above estimate even in a challenging environment, aided by Covid-19 tests as well as speedy recovery in base business.
Covid-19 and allied tests contributed 21.6% to sales. Other revenues grew 8.3% YoY.
Overall, revenue grew 38.0%, Ebitda margin was up 560/120 basis points YoY/QoQ to 30.7% and adjusted profit after tax was up 74.7% to Rs 945 million.
The base business has seen very good recovery and we expect healthy growth in coming quarters.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.